{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:07:27Z","timestamp":1759399647253,"version":"3.37.3"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82350101","82170200"],"award-info":[{"award-number":["82350101","82170200"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013152","name":"Shanghai Institute of Materia Medica Chinese Academy of Sciences","doi-asserted-by":"publisher","award":["2022YFA1004304","22077131","82322067"],"award-info":[{"award-number":["2022YFA1004304","22077131","82322067"]}],"id":[{"id":"10.13039\/501100013152","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004204","name":"Tongji University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004204","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.bmc.2024.117843","type":"journal-article","created":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T23:30:55Z","timestamp":1721691055000},"page":"117843","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Design, synthesis, and biological evaluation of novel 1-amido-2-one-4-thio-deoxypyranose as potential antitumor agents for multiple myeloma"],"prefix":"10.1016","volume":"111","author":[{"given":"Xiaomei","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanfeng","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuejie","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiguo","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5498-6328","authenticated-orcid":false,"given":"Zhaoyin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shushan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qikai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhufeng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Jacob Bunu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianming","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4279-4596","authenticated-orcid":false,"given":"Bo","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9679-9934","authenticated-orcid":false,"given":"Jingshan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haji","family":"Akber Aisa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3063-8473","authenticated-orcid":false,"given":"Zhijian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jumei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6699-5299","authenticated-orcid":false,"given":"Weiliang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2024.117843_b0005","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1021\/cr940283b","article-title":"Glycobiology: Toward Understanding the Function of Sugars","volume":"96","author":"Dwek","year":"1996","journal-title":"Chem Rev"},{"key":"10.1016\/j.bmc.2024.117843_b0010","doi-asserted-by":"crossref","first-page":"7428","DOI":"10.1021\/jm8006257","article-title":"Targeting the delivery of glycan-based paclitaxel prodrugs to cancer cells via glucose transporters","volume":"51","author":"Lin","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117843_b0015","doi-asserted-by":"crossref","first-page":"9694","DOI":"10.1039\/D2CS00379A","article-title":"Glycosidase activated prodrugs for targeted cancer therapy","volume":"51","author":"Martin","year":"2022","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.bmc.2024.117843_b0020","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s41568-020-00320-2","article-title":"The metabolism of cancer cells during metastasis","volume":"21","author":"Bergers","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bmc.2024.117843_b0025","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1126\/science.123.3191.309","article-title":"On the Origin of Cancer Cells","volume":"123","author":"Warburg","year":"1956","journal-title":"Science"},{"key":"10.1016\/j.bmc.2024.117843_b0030","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1039\/c3sc22205e","article-title":"Glucose conjugation for the specific targeting and treatment of cancer","volume":"4","author":"Calvaresi","year":"2013","journal-title":"Chem Sci"},{"key":"10.1016\/j.bmc.2024.117843_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113633","article-title":"Application of carbohydrates in approved small molecule drugs: A review","volume":"223","author":"Jiang","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2024.117843_b0040","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1039\/D0SC00954G","article-title":"Inhibiting cancer metabolism by aromatic carbohydrate amphiphiles that act as antagonists of the glucose transporter GLUT1","volume":"11","author":"Brito","year":"2020","journal-title":"Chem Sci"},{"key":"10.1016\/j.bmc.2024.117843_b0045","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s002800050248","article-title":"D-19575\u2013a sugar-linked isophosphoramide mustard derivative exploiting transmembrane glucose transport","volume":"35","author":"Pohl","year":"1995","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bmc.2024.117843_b0050","doi-asserted-by":"crossref","first-page":"10350","DOI":"10.1021\/acs.jmedchem.1c00793","article-title":"Carbohydrate-Based NK1R Antagonists with Broad-Spectrum Anticancer Activity","volume":"64","author":"Recio","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117843_b0055","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016","volume":"4","author":"Cowan","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.bmc.2024.117843_b0060","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"Van de Donk","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.bmc.2024.117843_b0065","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and Management of Multiple Myeloma: A Review","volume":"327","author":"Cowan","year":"2022","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.bmc.2024.117843_b0070","doi-asserted-by":"crossref","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","volume":"3","author":"Kumar","year":"2017","journal-title":"Multiple Myeloma. Nat Rev Dis Primers."},{"key":"10.1016\/j.bmc.2024.117843_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107579","article-title":"The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges","volume":"213","author":"Tundo","year":"2020","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.bmc.2024.117843_b0080","first-page":"193","article-title":"Old and new generation proteasome inhibitors in multiple myeloma","volume":"62","author":"Montefusco","year":"2020","journal-title":"Panminerva Med"},{"key":"10.1016\/j.bmc.2024.117843_b0085","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/ejh.12749","article-title":"A practical review on carfilzomib in multiple myeloma","volume":"96","author":"Muchtar","year":"2016","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bmc.2024.117843_b0090","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S0268-960X(10)70004-7","article-title":"Lenalidomide mode of action: linking bench and clinical findings","volume":"24","author":"Davies","year":"2010","journal-title":"Blood Rev"},{"key":"10.1016\/j.bmc.2024.117843_b0095","doi-asserted-by":"crossref","first-page":"7131802","DOI":"10.1155\/2020\/7131802","article-title":"Efficacy of Panobinostat for the Treatment of Multiple Myeloma","volume":"2020","author":"Eleutherakis-Papaiakovou","year":"2020","journal-title":"J Oncol"},{"key":"10.1016\/j.bmc.2024.117843_b0100","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3390\/ph9010003","article-title":"The Role of Immunotherapy in Multiple Myeloma","volume":"9","author":"Kocoglu","year":"2016","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.bmc.2024.117843_b0105","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s11523-021-00827-0","article-title":"Isatuximab: A Review of Its Use in Multiple Myeloma","volume":"16","author":"Frampton","year":"2021","journal-title":"Target Oncol"},{"key":"10.1016\/j.bmc.2024.117843_b0110","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1200\/JOP.18.00111","article-title":"Present and Future of Immunotherapy in the Management of Multiple Myeloma","volume":"14","author":"Baljevic","year":"2018","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.bmc.2024.117843_b0115","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bmc.2024.117843_b0120","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/ajh.26161","article-title":"Current approaches to management of high-risk multiple myeloma","volume":"96","author":"Goldman-Mazur","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bmc.2024.117843_b0125","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2147\/JEP.S265288","article-title":"Novel Experimental Drugs for Treatment of Multiple Myeloma","volume":"13","author":"Offidani","year":"2021","journal-title":"J Exp Pharmacol"},{"key":"10.1016\/j.bmc.2024.117843_b0130","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nrclinonc.2016.122","article-title":"Genomic complexity of multiple myeloma and its clinical implications","volume":"14","author":"Manier","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bmc.2024.117843_b0135","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood-2018-03-840132","article-title":"Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma","volume":"132","author":"Walker","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.bmc.2024.117843_b0140","doi-asserted-by":"crossref","first-page":"4527","DOI":"10.1038\/ncomms5527","article-title":"TRIP13 promotes error-prone nonhomologous end joining and induces chemoresistance in head and neck cancer","volume":"5","author":"Banerjee","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2024.117843_b0145","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.csbj.2019.06.005","article-title":"Insights into a Crucial Role of TRIP13 in Human Cancer","volume":"17","author":"Lu","year":"2019","journal-title":"Comput Struct Biotechnol J"},{"key":"10.1016\/j.bmc.2024.117843_b0150","doi-asserted-by":"crossref","first-page":"6660","DOI":"10.12659\/MSM.917112","article-title":"Thyroid Receptor-Interacting Protein 13 is Correlated with Progression and Poor Prognosis in Bladder Cancer","volume":"25","author":"Niu","year":"2019","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.bmc.2024.117843_b0155","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41419-018-0434-z","article-title":"TRIP13 promotes tumor growth and is associated with poor prognosis in colorectal cancer","volume":"9","author":"Sheng","year":"2018","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.bmc.2024.117843_b0160","doi-asserted-by":"crossref","first-page":"26718","DOI":"10.18632\/oncotarget.14957","article-title":"TRIP13 impairs mitotic checkpoint surveillance and is associated with poor prognosis in multiple myeloma","volume":"8","author":"Tao","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bmc.2024.117843_b0165","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/0008-5472.CAN-18-3987","article-title":"A Small-Molecule Inhibitor Targeting TRIP13 Suppresses Multiple Myeloma Progression","volume":"80","author":"Wang","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmc.2024.117843_b0170","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1002\/1878-0261.13201","article-title":"DCZ0415, a small-molecule inhibitor targeting TRIP13, inhibits EMT and metastasis via inactivation of the FGFR4\/STAT3 axis and the Wnt\/\u03b2-catenin pathway in colorectal cancer","volume":"16","author":"Agarwal","year":"2022","journal-title":"Mol Oncol"},{"key":"10.1016\/j.bmc.2024.117843_b0175","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1186\/s12967-023-04739-7","article-title":"The novel norcantharidin derivative DCZ5417 suppresses multiple myeloma progression by targeting the TRIP13-MAPK-YWHAE signaling pathway","volume":"21","author":"Wang","year":"2023","journal-title":"J Transl Med"},{"key":"10.1016\/j.bmc.2024.117843_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2023.129590","article-title":"Design and synthesis of cantharidin derivative DCZ5418 as a TRIP13 inhibitor with anti-multiple myeloma activity in vitro and in vivo","volume":"98","author":"Dong","year":"2024","journal-title":"Bioorganic Med Chem Lett."},{"key":"10.1016\/j.bmc.2024.117843_b0185","article-title":"Zolinose compound, preparation method therefor and use thereof","author":"Zhu","year":"2022","journal-title":"CN114369125A"},{"key":"10.1016\/j.bmc.2024.117843_b0190","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1021\/acs.jmedchem.6b00788","article-title":"Covalent Modifiers: A Chemical Perspective on the Reactivity of \u03b1, \u03b2-Unsaturated Carbonyls with Thiols via Hetero-Michael Addition Reactions","volume":"60","author":"Jackson","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117843_b0195","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1248\/cpb.44.80","article-title":"Chemistry of Oxo-Sugars. III.Transformations of 2- and 3-Oxoglycosides in a Pyridine Solution","volume":"44","author":"Tsuda","year":"1996","journal-title":"Chem Pharm Bull"},{"key":"10.1016\/j.bmc.2024.117843_b0200","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1055\/s-0033-1341106","article-title":"Selectivity Reversal during Thia-Michael Additions Using Tetrabutylammonium Hydroxide: Operationally Simple and Extremely High Turnover","volume":"46","author":"Nicponski","year":"2014","journal-title":"Synthesis"},{"key":"10.1016\/j.bmc.2024.117843_b0205","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/10408347.2014.881250","article-title":"Surface plasmon resonance (SPR) biosensors in pharmaceutical analysis","volume":"45","author":"Olaru","year":"2015","journal-title":"Crit Rev Anal Chem"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089624002578?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089624002578?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:44:26Z","timestamp":1724287466000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089624002578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":41,"alternative-id":["S0968089624002578"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2024.117843","relation":{},"ISSN":["0968-0896"],"issn-type":[{"type":"print","value":"0968-0896"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and biological evaluation of novel 1-amido-2-one-4-thio-deoxypyranose as potential antitumor agents for multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2024.117843","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117843"}}